Dyadic International, Inc. operates as a biotechnology company with operations in the United States, the Netherlands, and Poland. The company uses its patented and proprietary technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture, and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The company involves in the licensing of its patented and proprietary technologies and the sale of its proprietary enzymes. Its research and development activities focus on its patented and proprietary fungal strains and associated technologies. It uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. It manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, food, brewing, alcohol, alternative fuels, textile, and pulp and paper industries. The company also utilizes an integrated technology platform based on its patented and proprietary C1 fungus (the C1 platform technology), which enables the development and manufacture of proteins and enzymes for various market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. In addition to facilitating the development and production of enzymes, the C1 platform technology performs the same function of other biological products for the biopharmaceutical industry, such as antibodies, proteins, enzymes, and polypeptides. Strategic Alliances In December 2009, Dyadic International, Inc. announced that it has extended its collaboration with Scripps Research Institute by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ('C1'). History Dyadic International, Inc. was founded in 2002.
dyadic international inc
(DYAI:OTC Markets Group Inc - Premier QX)
140 Intracoastal Pointe Drive
Jupiter, FL 33477
|Koninklijke DSM NV||€50.28 EUR||+0.07|
|Lonza Group AG||SFr.116.40 CHF||-0.30|
|Merck KGaA||€69.52 EUR||+1.00|
|Novozymes A/S||kr259.90 DKK||+2.30|
|Teva Pharmaceutical Industries Ltd||$52.16 USD||-0.25|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact DYADIC INTERNATIONAL INC, please visit www.dyadic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.